Odronextamab ash presentations underscore impressive potential in earlier lines of treatment and additional types of lymphoma

Odronextamab monotherapy led to complete responses in all patients with previously untreated follicular lymphoma evaluable for efficacy, per initial results from the safety lead-in portion of the confirmatory phase 3 olympia-1 trial
REGN Ratings Summary
REGN Quant Ranking